People · Operator
Named in public records as an officer, director or promoter · active 2018–2024 · Biotechnology, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Apic Bio, Inc. | — | Biotechnology | Series C | $55.4M | $195.8M | 2018 |
| SYMPHONY42 Corp | — | Other Technology | Pre-Seed | $1.1M | $1.3M | 2023 |
John Reilly at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside John Reilly on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jason Dinges | 1 | 8 |
| Stephen Hoffman | 1 | 7 |
| Dave Blundin | 1 | 4 |
| Sean Fenlon | 1 | 2 |
| Ramon Castro | 1 | 2 |
| Michael Wolek | 1 | 1 |
| Stephanie O'Brien, J.D. | 1 | 1 |
| Christian Mueller | 1 | 1 |
| Mark Fruhling | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.